Cost-effectiveness of novel first-line treatment regimens for tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 5, 2013, Pages 590-596

  Owens, J P ^a   Fofana, M O ^a   Dowdy, David W ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tuberculosis agents; Cost benefit analysis; Drugs, investigational

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEARS; DRUG COST; DRUG EFFICACY; HEALTH CARE DELIVERY; HUMAN; INTERMETHOD COMPARISON; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, ECONOMIC; PUBLIC SECTOR; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84876856559     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0776     Document Type: Article

References (29)

1. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 1982; 63: 89-98.
2. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143 (4 Pt 1): 700-706.
3. Singapore Tuberculosis Service/British Medical Research Council. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 779-783.
4. Iseman M D. Tuberculosis therapy: past, present and future. Eur Respir J 2002; 36 (Suppl): 87S-94S. (Pubitemid 34774191)
5. Snider D E Jr, Cohn D L, Davidson P T, Hershfield E S, Smith M H, Sutton F D Jr. Standard therapy for tuberculosis: 1985. Chest 1985; 87 (2 Suppl): 117S-124S.
6. Steffen R, Menzies D, Oxlade O, et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS ONE 2010; 5: e14014.
7. Menzies D, Lewis M, Oxlade O. Costs for tuberculosis care in Canada. Can J Public Health 2008; 99: 391-396.
8. Spence D P, Hotchkiss J, Williams C S, Davies P D. Tuberculosis and poverty. BMJ 1993; 307: 759-761. (Pubitemid 23279319)
9. Kruk M E, Schwalbe N R, Aguiar C A. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health 2008; 13: 703-712. (Pubitemid 351561604)
10. Munro S A, Lewin S A, Smith H J, Engel M E, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
11. Ginsberg A M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-559.
12. Spigelman M K. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007; 196 (Suppl 1): S28-S34. (Pubitemid 47206082)
13. Conde M B, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
14. World Health Organization. Global price reporting mechanism. Geneva, Switzerland: WHO, 2013. http://www.who.int/hiv/amds/gprm/en/ Accessed January 2013.
15. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
16. Tiemersma E W, van der Werf M J, Borgdorff M W, Williams B G, Nagelkerke N J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 2011; 6: e17601.
17. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Am Rev Respir Dis 1981; 124: 138-142.
18. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
19. Stop TB Partnership. Global Drug Facility: list of drugs available. Geneva, Switzerland: WHO, 2013. http://www.stoptb.org/gdf/drugsupply/pc2.asp? CLevel=3&CParent=10 Accessed January 2013.
20. Jonnalagada S, Harries A D, Zachariah R, et al. The timing of death in patients with tuberculosis who die during antit uberculosis treatment in Andhra Pradesh, South India. BMC Public Health 2011; 11: 921.
21. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001; 5: 1000-1005. (Pubitemid 33134749)
22. Tekle B, Mariam D H, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. Int J Tuberc Lung Dis 2002; 6: 573-579. (Pubitemid 36898181)
23. World Health Organization. Tuberculosis country profiles. Geneva, Switzerland: WHO, 2013. http://www.who.int/tb/country/data/profiles/en/index. html Accessed March 2013.
24. World Bank. Life expectancy. Washington DC, USA: World Bank, 2012. http://www.google.com/publicdata/explore?ds=d5bncppjof8f9-&ctype= l&strail=false&nselm=h&hl=en&dl=en#!ctype=l&strail= false&bcs=d&nselm=h&met- y=sp-dyn-le00-in&scale- y=lin&ind- y=false&rdim=region&ifdim=region&tdim=true&hl=en-US&dl= en&ind=false Accessed January 2013.
25. Murray C J L, Lopez A D. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA, USA: Harvard School of Public Health (on behalf of the World Health Organization and the World Bank), 1996.
26. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva, Switzerland: World Health Organization, 2001.
27. World Bank. World development indicators. Washington DC, USA: World Bank, 2012. http://www.google.com/publicdata/overview?ds=d5bncppjof8f9-&ctype= l&strail=false&nselm=h&hl=en&dl=en Accessed January 2013.
28. Dorman S E, Johnson J L, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
29. Grosset J H, Singer T G, Bishai W R. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.